-
1
-
-
0027172047
-
A current view of tamoxifen for the treatment and prevention of breast cancer
-
Jordan VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110:507-17.
-
(1993)
Br J Pharmacol
, vol.110
, pp. 507-517
-
-
Jordan, V.C.1
-
2
-
-
0032537990
-
Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
-
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1371-1388
-
-
Fisher, B.1
Costantino, J.P.2
Wickerham, D.L.3
Redmond, C.K.4
Kavanah, M.5
Cronin, W.M.6
Vogel, V.7
Robidoux, A.8
Dimitrov, N.9
Atkins, J.10
Daly, M.11
Wieand, S.12
-
3
-
-
0021960977
-
Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens
-
Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8.
-
(1985)
Cancer Treat Rep
, vol.69
, pp. 237-238
-
-
Killackey, M.A.1
Hakes, T.B.2
Pierce, V.K.3
-
4
-
-
0028053224
-
Risk of endometrial cancer after tamoxifen treatment of breast cancer
-
van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
-
(1994)
Lancet
, vol.343
, pp. 448-452
-
-
van Leeuwen, F.E.1
Benraadt, J.2
Coebergh, J.W.3
Kiemeney, L.A.4
Gimbrere, C.H.5
Otter, R.6
Schouten, L.J.7
Damhuis, R.A.8
Bontenbal, M.9
Diepenhorst, F.W.10
-
5
-
-
0033530255
-
Tamoxifen therapy for breast cancer and endometrial cancer risk
-
Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62.
-
(1999)
J Natl Cancer Inst
, vol.91
, pp. 1654-1662
-
-
Bernstein, L.1
Deapen, D.2
Cerhan, J.R.3
Schwartz, S.M.4
Liff, J.5
McGann-Maloney, E.6
Perlman, J.A.7
Ford, L.8
-
6
-
-
3042653655
-
Genotoxic mechanism of tamoxifen in developing endometrial cancer
-
Kim SY, Suzuki N, Laxmi YRS, Shibutani S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev 2004;36:199-218.
-
(2004)
Drug Metab Rev
, vol.36
, pp. 199-218
-
-
Kim, S.Y.1
Suzuki, N.2
Laxmi, Y.R.S.3
Shibutani, S.4
-
7
-
-
0034989609
-
Understanding the genotoxicity of tamoxifen?
-
Phillips DH. Understanding the genotoxicity of tamoxifen? Carcinogenesis 2001;22:839-49.
-
(2001)
Carcinogenesis
, vol.22
, pp. 839-849
-
-
Phillips, D.H.1
-
8
-
-
0036347450
-
The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial
-
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 2002;3:153-9.
-
(2002)
Clin Breast Cancer
, vol.3
, pp. 153-159
-
-
Vogel, V.G.1
Costantino, J.P.2
Wickerham, D.L.3
Cronin, W.M.4
Wolmark, N.5
-
9
-
-
0033575083
-
The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial
-
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999;281:2189-97.
-
(1999)
JAMA
, vol.281
, pp. 2189-2197
-
-
Cummings, S.R.1
Eckert, S.2
Krueger, K.A.3
Grady, D.4
Powles, T.J.5
Cauley, J.A.6
Norton, L.7
Bjarnason, N.H.8
Morrow, M.9
Lippman, M.E.10
Black, D.11
Glusman, J.E.12
-
10
-
-
0035120523
-
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial
-
Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34.
-
(2001)
Breast Cancer Res Treat
, vol.65
, pp. 125-134
-
-
Cauley, J.A.1
Norton, L.2
Lippman, M.E.3
Eckert, S.4
Krueger, K.A.5
Purdie, D.W.6
Farrerons, J.7
Karasik, A.8
Mellstrom, D.9
Ng, K.W.10
Stepan, J.J.11
Powles, T.J.12
-
11
-
-
0030664688
-
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
-
Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
-
(1997)
N Engl J Med
, vol.337
, pp. 1641-1647
-
-
Delmas, P.D.1
Bjarnason, N.H.2
Mitlak, B.H.3
Ravoux, A.C.4
Shah, A.S.5
Huster, W.J.6
Draper, M.7
Christiansen, C.8
-
12
-
-
77951580891
-
-
Available at, Accessed September 14, 2007
-
FDA: FDA approves new uses for Evista. Available at http://www.fda.gov/ bbs/topics/NEWS/2007/NEW01698.html. Accessed September 14, 2007.
-
FDA approves new uses for Evista
-
-
-
13
-
-
0036266936
-
Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance
-
Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 2002;30:694-700.
-
(2002)
Drug Metab Dispos
, vol.30
, pp. 694-700
-
-
Kemp, D.C.1
Fan, P.W.2
Stevens, J.C.3
-
14
-
-
18844431909
-
Species- and disposition model-dependent metabolism of raloxifene in gut and liver: Role of UGT1A10
-
Jeong EJ, Liu Y, Lin H, Hu M. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 2005;33:785-94.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 785-794
-
-
Jeong, E.J.1
Liu, Y.2
Lin, H.3
Hu, M.4
-
16
-
-
0023229345
-
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
-
Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4.
-
(1987)
Cancer Res
, vol.47
, pp. 4020-4024
-
-
Gottardis, M.M.1
Jordan, V.C.2
-
17
-
-
0041525251
-
Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs
-
Heimbach T, Oh DM, Li LY, Rodriguez-Hornedo N, Garcia G, Fleisher D. Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. Int J Pharm 2003;261:81-92.
-
(2003)
Int J Pharm
, vol.261
, pp. 81-92
-
-
Heimbach, T.1
Oh, D.M.2
Li, L.Y.3
Rodriguez-Hornedo, N.4
Garcia, G.5
Fleisher, D.6
-
18
-
-
41149085588
-
-
Chen Z, Gao Q, Yuan L, Yuan L, Tang Z, Wu Z. Application of novel benzothiophene derivatives in treating postmenstrual syndrome and other estrogen-related diseases. Faming Zhuanli Shenqing Gongkai Shuomingshu (2002), 20pp. CN 1370533 A 20020925 (written in Chinese). Application: CN 2001-104434 20010227. CAN 139:271010.
-
Chen Z, Gao Q, Yuan L, Yuan L, Tang Z, Wu Z. Application of novel benzothiophene derivatives in treating postmenstrual syndrome and other estrogen-related diseases. Faming Zhuanli Shenqing Gongkai Shuomingshu (2002), 20pp. CN 1370533 A 20020925 (written in Chinese). Application: CN 2001-104434 20010227. CAN 139:271010.
-
-
-
-
19
-
-
41149142456
-
-
Asao T, Takeda S, Sugimoto Y, Toko T, Yamada Y, Ogawa K, Unemi N. Preparation of butenylphenyl phosphates as drugs for mammary cancer and anovulatory sterility. PCT Int. Appl. 44 pp.WO 8707609 A (1987).
-
Asao T, Takeda S, Sugimoto Y, Toko T, Yamada Y, Ogawa K, Unemi N. Preparation of butenylphenyl phosphates as drugs for mammary cancer and anovulatory sterility. PCT Int. Appl. 44 pp.WO 8707609 A (1987).
-
-
-
-
20
-
-
0035023196
-
Differential SERM activation of the estrogen receptors (ERα and ERβ) at AP-1 sites
-
Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ERα and ERβ) at AP-1 sites. Chem Biol 2001;8:427-36.
-
(2001)
Chem Biol
, vol.8
, pp. 427-436
-
-
Weatherman, R.V.1
Clegg, N.J.2
Scanlan, T.S.3
-
21
-
-
19944427846
-
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor β with low uterotrophic effect
-
Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asao T, Buzdar AU, Terada T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor β with low uterotrophic effect. Clin Cancer Res 2005;11:315-22.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 315-322
-
-
Yamamoto, Y.1
Shibata, J.2
Yonekura, K.3
Sato, K.4
Hashimoto, A.5
Aoyagi, Y.6
Wierzba, K.7
Yano, S.8
Asao, T.9
Buzdar, A.U.10
Terada, T.11
-
22
-
-
0028861896
-
Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma
-
Toko T, Shibata J, Sugimoto Y, Yamaya H, Yoshida M, Ogawa K, Matsushima E. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma. Cancer Chemother Pharmacol 1995;37:7-13.
-
(1995)
Cancer Chemother Pharmacol
, vol.37
, pp. 7-13
-
-
Toko, T.1
Shibata, J.2
Sugimoto, Y.3
Yamaya, H.4
Yoshida, M.5
Ogawa, K.6
Matsushima, E.7
-
23
-
-
27544464442
-
Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of α-hydroxytamoxifen in rat and human livers
-
Kim SY, Laxmi YRS, Suzuki N, Ogura K, Watabe T, Duffel MW, Shibutani S. Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of α-hydroxytamoxifen in rat and human livers. Drug Metab Dispos 2005;33:1673-8.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 1673-1678
-
-
Kim, S.Y.1
Laxmi, Y.R.S.2
Suzuki, N.3
Ogura, K.4
Watabe, T.5
Duffel, M.W.6
Shibutani, S.7
-
24
-
-
0017184389
-
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
-
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
-
(1976)
Anal Biochem
, vol.72
, pp. 248-254
-
-
Bradford, M.M.1
-
25
-
-
0020582094
-
Effects of a new antiestrogen. Keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on. LH and prolactin levels
-
Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen. Keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on. LH and prolactin levels. Life Sci 1983;32:2869-75.
-
(1983)
Life Sci
, vol.32
, pp. 2869-2875
-
-
Clemens, J.A.1
Bennett, D.R.2
Black, L.J.3
Jones, C.D.4
-
26
-
-
0036494109
-
Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models
-
Brady H, Desai S, Gayo-Fung LM, Khammungkhune S, McKie JA, O'Leary E, Pascasio L, Sutherland MK, Anderson DW, Bhagwat SS, Stein B. Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models. Cancer Res 2002;62:1439-42.
-
(2002)
Cancer Res
, vol.62
, pp. 1439-1442
-
-
Brady, H.1
Desai, S.2
Gayo-Fung, L.M.3
Khammungkhune, S.4
McKie, J.A.5
O'Leary, E.6
Pascasio, L.7
Sutherland, M.K.8
Anderson, D.W.9
Bhagwat, S.S.10
Stein, B.11
-
27
-
-
0042143281
-
Targeted prodrug design to optimize drug delivery
-
article E6
-
Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2002;2:article E6.
-
(2002)
AAPS PharmSci
, Issue.2
-
-
Han, H.K.1
Amidon, G.L.2
-
28
-
-
33745282138
-
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
-
Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL III, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-51.
-
(2006)
JAMA
, vol.295
, pp. 2742-2751
-
-
Land, S.R.1
Wickerham, D.L.2
Costantino, J.P.3
Ritter, M.W.4
Vogel, V.G.5
Lee, M.6
Pajon, E.R.7
Wade III, J.L.8
Dakhil, S.9
Lockhart Jr, J.B.10
Wolmark, N.11
Ganz, P.A.12
-
29
-
-
33745876266
-
Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
-
Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Komitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37.
-
(2006)
N Engl J Med
, vol.355
, pp. 125-137
-
-
Barrett-Connor, E.1
Mosca, L.2
Collins, P.3
Geiger, M.J.4
Grady, D.5
Komitzer, M.6
McNabb, M.A.7
Wenger, N.K.8
|